…n CONGRESS HIGHLIGHTS – THURSDAY EDITION Multiple sclerosis Alemtuzumab – 9-year data Siponimod long-term data Stopping DMTs in inactive patients Changing definition of SPMS How prognostic is confirmed disability progression? Quetiapine and remyelination Narcolepsy New data for solriamfetol Clinical tip of the day Multiple sclerosis Alemtuzumab – 9-year data: A 9-year analysis of the CARE-MS II cohort found that 41% have not required additional th…

…240 mg BID, 192 patients received continuous DMF for 10 years. The relapse-free rate was 51%; the median time to relapse was 518 weeks. ARR in years 0-10 was 0.107. At 10 years, EDSS remained <3.5 in 89%, and 64% had no confirmed disability progression. QoL measures remained stable. Ocrelizumab – B cell repopulation: Ocrelizumab produces a rapid, profound depletion of B cells, but its impact on different B cell subsets is not uniform (Shinoda et…

…. -6.4) at 6 months with further improvement at 12 months. SUNRISE I, a one-month comparison of lemborexant vs. zolpidem and placebo, was published last year (Rosenberg et al. JAMA Netw Open 2019;2:e1918254. Multiple sclerosis MSBase – Long-term disability outcomes with DMTs: An analysis by the MSBase group (n=24,884) estimated that disease-modifying therapies (DMTs) reduce long-term disability accrual by about 26% compared to no treatment (Kalinc…